Financial Performance - The company's operating revenue for Q3 2021 was ¥142,882,982.40, a decrease of 21.26% compared to the same period last year, and a year-to-date revenue of ¥405,253,231.61, down 55.49% year-on-year[3]. - The net profit attributable to shareholders for Q3 2021 was ¥3,522,074.22, a decline of 46.62% year-on-year, with a year-to-date net profit of ¥14,738,567.26, down 83.96% compared to the previous year[3]. - The basic earnings per share for Q3 2021 was ¥0.012, a decrease of 46.62%, and the diluted earnings per share also decreased by 46.62% to ¥0.012[4]. - Total operating revenue for the first three quarters of 2021 was CNY 405,253,231.61, a decrease of 55.5% compared to CNY 910,547,636.67 in the same period of 2020[16]. - Net profit for Q3 2021 was CNY 14,519,060.14, a decline of 84.7% compared to CNY 92,631,179.32 in Q3 2020[18]. - Operating profit for Q3 2021 was CNY 19,210,439.71, a decrease of 81.3% from CNY 102,445,407.46 in Q3 2020[17]. - Total comprehensive income for Q3 2021 was CNY 14,519,060.14, a significant drop from CNY 92,631,179.32 in Q3 2020[18]. Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period was -¥32,528,313.83, representing a decrease of 123.06% year-on-year[3]. - Cash flow from operating activities for the first three quarters of 2021 was negative CNY 32,528,313.83, compared to positive CNY 141,031,803.96 in the same period of 2020[21]. - The company reported a net cash outflow from investing activities of CNY 234,883,824.25 in Q3 2021, compared to a net outflow of CNY 83,340,175.25 in Q3 2020[21]. - Total cash outflow from financing activities was $528.65 million, compared to $297.11 million in the previous year, representing an increase of 77.8%[22]. - Net cash flow from financing activities was $124.72 million, up from $85.27 million, indicating a growth of 46.3% year-over-year[22]. - The beginning cash and cash equivalents balance was $311.94 million, up from $188.67 million, reflecting a growth of 65.3% year-over-year[22]. - The ending cash and cash equivalents balance was $167.59 million, down from $325.57 million, indicating a decline of 48.6%[22]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,260,948,593.24, an increase of 17.56% from the end of the previous year[4]. - Current assets totaled RMB 599,342,501.34, down from RMB 644,235,238.02 at the end of 2020, primarily due to a decrease in cash and cash equivalents[13]. - Accounts receivable increased to RMB 131,615,649.15 from RMB 94,511,722.38, reflecting a growth of approximately 39.3% year-over-year[13]. - Inventory rose significantly to RMB 166,452,134.24, compared to RMB 118,375,103.72 at the end of 2020, indicating a growth of about 40.6%[13]. - Total liabilities increased to RMB 567,053,197.43 from RMB 371,840,580.60, representing a growth of approximately 52.5%[15]. - Short-term borrowings surged to RMB 341,318,240.00, up from RMB 177,624,500.00, marking an increase of about 92.0%[14]. - The company's equity attributable to shareholders decreased slightly to RMB 688,726,530.89 from RMB 696,791,263.63[15]. - The company reported a decrease in cash and cash equivalents to RMB 197,239,620.62 from RMB 325,210,428.12, a decline of approximately 39.3%[13]. Operational Challenges - The decrease in revenue and profit was primarily due to a reduction in sales of epidemic prevention protective products and a decline in gross profit margin[8]. - The company experienced a significant increase in inventory levels due to rising raw material prices and the production of nitrile gloves, impacting cash flow[8]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 17,097[10]. Research and Development - Research and development expenses for Q3 2021 were CNY 22,822,980.02, up 12.3% from CNY 20,318,391.23 in Q3 2020[17]. Corporate Activities - The company has not disclosed any new product developments or market expansion strategies during this reporting period[12]. - There are no significant mergers or acquisitions reported in the current quarter[12]. - The company has not adopted the new leasing standards for the current year[22].

Financial Performance - The company's operating revenue for the first half of 2021 was ¥262,370,249.21, a decrease of 64.01% compared to ¥729,093,174.95 in the same period last year[19]. - The net profit attributable to shareholders for the first half of 2021 was ¥11,216,493.04, down 86.52% from ¥83,215,991.64 in the previous year[19]. - The net cash flow from operating activities was -¥30,602,512.86, a decline of 121.60% compared to ¥141,696,341.32 in the same period last year[19]. - Basic earnings per share for the first half of 2021 were ¥0.038, down 86.62% from ¥0.284 in the same period last year[20]. - The weighted average return on net assets decreased by 12.25 percentage points to 1.60% from 13.85% in the previous year[20]. - The company reported a significant decline in net profit after deducting non-recurring gains and losses, with a decrease of 91.79% to ¥0.023 per share[20]. - The company's operating revenue decreased due to a reduction in sales of epidemic prevention protective products[21]. - Net profit attributable to shareholders of the listed company decreased primarily due to the decline in operating revenue[21]. - Earnings per share decreased mainly due to the reduction in net profit attributable to shareholders of the listed company[21]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,216,831,313.95, an increase of 13.44% from ¥1,072,645,455.80 at the end of the previous year[19]. - The net assets attributable to shareholders decreased by 1.66% to ¥685,204,456.67 from ¥696,791,263.63 at the end of the previous year[19]. - Total liabilities reached CNY 526,359,635.07, compared to CNY 371,840,580.60, showing an increase of around 41.5%[129]. - Short-term borrowings surged to CNY 321,796,260.00 from CNY 177,624,500.00, representing an increase of approximately 81.0%[129]. Research and Development - The company invested RMB 13.91 million in R&D, an increase of 26.56% compared to the same period last year, focusing on new external preparations and transdermal delivery technology[46]. - The company has developed a strong technical research and development capability, leading in technologies such as adhesive perforation and high water absorption hydrogel preparation[38]. - The company has established a collaborative research platform with Zhejiang University, focusing on transdermal drug delivery technologies and micro-needle drug delivery systems[39]. Market Position and Strategy - The company has established a strong market position as a leading medical device manufacturer in China, leveraging over 30 years of operational experience and the cluster effect of the textile industry in the Yangtze River Delta region[37]. - The company primarily operates under an ODM model, while also increasing the development and market expansion of its own brand products, including first aid kits, sports protection products, and protective gear[35]. - The company is actively pursuing international markets, but faces risks from geopolitical and economic factors that could impact its operations[69]. - The company is exploring potential mergers and acquisitions to strengthen its market position[153]. Compliance and Governance - The company has obtained GMP certification and relevant production licenses, ensuring compliance with national quality management standards for medical devices[71]. - The company emphasizes compliance with the Company Law and Securities Law in all share repurchase and purchase activities[90]. - The company has passed resolutions to revise governance documents, reflecting ongoing improvements in corporate governance practices[76]. Environmental and Social Responsibility - The company has implemented measures for wastewater management, including connecting domestic wastewater to the local sewage treatment plant[82]. - The company has established solid waste disposal protocols, with hazardous waste managed by qualified units[84]. - The company has developed an emergency response plan for environmental incidents, enhancing its emergency management capabilities[84]. Shareholder Commitments and Stock Management - The company’s controlling shareholder, Li Ping, committed to purchasing company shares at a price not exceeding 110% of the latest audited net asset value per share, with a minimum purchase of 3% of total shares within 90 days of the announcement[90]. - The company plans to issue convertible bonds, which may enhance its capital structure and provide funding for future projects[77]. - The company has established a three-year shareholder return plan for 2021-2023, aiming to enhance shareholder value[77]. Legal and Regulatory Risks - The company is subject to regulatory risks due to the high level of government oversight in the pharmaceutical manufacturing industry[67]. - The company is involved in multiple significant lawsuits related to sales contract disputes with various entities, including Jiangsu Hantang International Trade Co., Ltd. and Shenzhen Xinhongmei Medical Equipment Co., Ltd.[99]. - The company has a pending lawsuit against Shen Yuzhong regarding a compensation amount of 602.17 thousand yuan, which is based on performance compensation from a share transfer agreement[101]. Future Outlook - Future performance guidance indicates a cautious outlook, with expectations of moderate growth in the upcoming quarters[153]. - The company plans to continue expanding its market presence and product offerings in the medical supplies sector[162].

Financial Performance - Operating revenue rose by 41.07% to CNY 141,682,428.93 year-on-year[5] - Net profit attributable to shareholders decreased by 3.23% to CNY 9,128,042.63 compared to the same period last year[5] - Basic earnings per share decreased by 3.22% to CNY 0.04054[5] - Total revenue for Q1 2021 reached ¥141,682,428.93, a 40.9% increase from ¥100,435,111.68 in Q1 2020[25] - Net profit for Q1 2021 was ¥8,980,922.60, compared to ¥9,289,562.19 in Q1 2020, showing a decrease of 3.3%[26] - The company's revenue for Q1 2021 reached ¥142,740,020.02, a 46.6% increase compared to ¥97,334,274.40 in Q1 2020[29] - Operating profit for Q1 2021 was ¥14,625,537.57, up 32.5% from ¥11,019,443.49 in Q1 2020[30] - Net profit for Q1 2021 was ¥13,766,598.77, representing a 40.1% increase from ¥9,814,291.57 in Q1 2020[30] Assets and Liabilities - Total assets increased by 5.12% to CNY 1,127,517,818.84 compared to the end of the previous year[5] - The company's total liabilities increased to ¥412,245,171.04, up from ¥371,840,580.60 at the end of the previous year[19] - The company's total assets as of March 31, 2021, amounted to ¥1,125,015,178.40, an increase from ¥1,066,133,986.78 at the end of 2020[22] - Total liabilities as of March 31, 2021, were ¥419,184,227.62, compared to ¥379,556,484.77 at the end of 2020, indicating an increase of 10.5%[23] - The company's equity totaled ¥705,830,950.78 as of March 31, 2021, up from ¥686,577,502.01 at the end of 2020, reflecting a growth of 2.1%[23] Cash Flow - Net cash flow from operating activities worsened, with a net outflow of CNY 54,987,217.80, an increase of 804.95% in outflow compared to the previous year[5] - The net cash flow from financing activities increased by 352.88% to ¥56,009,567.78, mainly due to an increase in short-term borrowings[12] - The company reported a net cash outflow from operating activities of ¥54,987,217.80 in Q1 2021, compared to a smaller outflow of ¥6,076,249.05 in Q1 2020[33] - Cash and cash equivalents at the end of Q1 2021 were ¥253,432,324.99, down from ¥160,352,139.36 at the end of Q1 2020[34] - Cash flow from financing activities generated a net inflow of $56.01 million, up from $12.37 million year-over-year[36] - The net decrease in cash and cash equivalents for the quarter was -$55.25 million, compared to -$3.17 million in the previous year[36] Shareholder Information - The total number of shareholders reached 19,776 at the end of the reporting period[9] - The largest shareholder, Li Ping, holds 43.39% of the shares, amounting to 97,711,575 shares[9] Research and Development - Research and development expenses rose to ¥7,577,590.98, reflecting a 104.27% increase year-on-year, attributed to higher R&D investments[11] - Research and development expenses increased to ¥7,577,590.98 in Q1 2021, up 104.5% from ¥3,709,559.07 in Q1 2020[29] Other Financial Metrics - The weighted average return on equity increased by 0.02 percentage points to 1.30%[5] - The company received government subsidies amounting to CNY 144,019.25 during the reporting period[7] - The company reported a total of CNY 121,813.00 in non-recurring gains and losses[7] - The company's management expenses increased by 88.59% to ¥15,181,487.51, primarily due to increased employee stock compensation[11] - Total operating costs for Q1 2021 were ¥133,269,629.14, up from ¥90,315,047.95 in Q1 2020, reflecting a 47.5% increase[26] - The company incurred a credit impairment loss of ¥2,728,518.64 in Q1 2021, significantly higher than ¥204,484.65 in Q1 2020[30] - The company raised ¥202,317,380.00 through borrowings in Q1 2021, compared to ¥50,780,000.00 in Q1 2020, showing increased financing activity[34]

Financial Performance - In 2020, the company's operating revenue reached ¥1,072,399,917.76, representing a 118.11% increase compared to ¥491,688,011.57 in 2019[20] - The net profit attributable to shareholders was ¥98,067,613.55, a significant increase of 249.60% from ¥28,051,595.53 in the previous year[20] - The net profit attributable to shareholders, excluding non-recurring gains and losses, was ¥86,701,465.59, up 275.58% from ¥23,084,715.39 in 2019[20] - Cash flow from operating activities amounted to ¥154,122,592.63, a 367.12% increase compared to ¥32,994,069.13 in 2019[21] - As of the end of 2020, total assets were ¥1,072,645,455.80, reflecting a 23.35% increase from ¥869,601,971.34 at the end of 2019[21] - The net assets attributable to shareholders increased by 23.51% to ¥696,791,263.63 from ¥564,157,337.40 in 2019[21] - Basic earnings per share increased by 164.71% to CNY 0.45 from CNY 0.17 in 2019[22] - The weighted average return on equity rose to 16.01%, an increase of 10.99 percentage points compared to 5.02% in 2019[22] Dividend Distribution - The company plans to distribute a cash dividend of ¥1.5 per 10 shares, totaling approximately ¥33,777,000.00, and to increase the share capital by 3 shares for every 10 shares held[5] - In 2019, the company distributed a cash dividend of RMB 0.5 per 10 shares, amounting to RMB 8,450,000[139] - The company has a profit distribution policy that mandates a minimum cash dividend of 25% of the distributable profit when conditions allow[133] - For mature companies without significant capital expenditure, the cash dividend should constitute at least 80% of the profit distribution[133] Business Operations and Strategy - The company’s main business includes the development, production, and sales of transdermal products, medical tapes, first aid kits, and protective equipment[29] - The increase in main business revenue was primarily driven by the surge in sales of pandemic-related protective products[24] - The company is positioned in the pharmaceutical manufacturing industry, specifically in the manufacturing of sanitary materials and medical supplies[29] - The company has established a strict supplier selection mechanism, evaluating suppliers based on qualifications, manufacturing capabilities, and quality management, with regular assessments conducted[36] - The company utilizes a "sales-driven production" model, organizing production based on customer demand, with a focus on timely preparation of raw materials for large clients[37] - The company has increased its focus on developing its own brand products, expanding into areas such as first aid kits and protective gear, alongside its ODM business model[38] Research and Development - The company invested 33.96 million yuan in R&D, a 52.30% increase compared to the previous year, focusing on new formulations and technology upgrades[58] - The company holds 30 Class I medical device registrations and 14 Class II medical device registrations, along with 3 drug registration certificates[58] - The company has established a research collaboration with Zhejiang University, focusing on transdermal drug delivery technologies, resulting in two national invention patents granted[48] - Major R&D projects included the development of antibacterial medical bandages with an investment of RMB 3,771,980.69, reflecting a 37.31% increase compared to the previous year[101] - The company is focusing on the research of transdermal drug delivery technologies, particularly in hydrogel formulations[92] Market Position and Industry Outlook - The company has a strong market position in the medical device industry, leveraging nearly 30 years of experience to meet domestic and international customer demands effectively[45] - The medical device industry is expected to continue growing, supported by favorable national policies and increasing domestic demand[87] - The overall concentration of the medical device industry in China is low, with many companies relying on traditional medical consumables for export, leading to increased market competition and pressure on profit levels[114] - The company aims to achieve a revenue target of 1.1 billion yuan and a profit target of 105 million yuan for the year 2021[117] Risk Management - The company has not identified any significant risks that could materially affect its operations during the reporting period[7] - The company recognizes risks such as industry policy changes, intensified market competition, and fluctuations in foreign exchange rates that could impact its operations[123][124][127] - The company faces risks related to product liability and potential litigation that could impact its reputation and operational capacity[128] - The ongoing pandemic has limited the company's production, procurement, and market sales, leading to uncertainty in its business operations[130] Corporate Governance and Compliance - The company is committed to ensuring the accuracy and completeness of its financial reports, as confirmed by its management[4] - The company has not made any adjustments to its profit distribution policy during the reporting period[138] - The company has maintained a focus on compliance and transparency in its financial reporting and legal obligations[153] Environmental and Social Responsibility - The company has implemented environmental protection measures, including a rainwater and sewage separation system to manage wastewater effectively[172] - The company has established a social responsibility management system, focusing on employee welfare and rights protection, including regular salary adjustments and social insurance contributions[170] - The company actively participates in social welfare activities, establishing a long-term donation mechanism to support charitable causes[171] Shareholder Information - The total number of restricted shares held by key personnel increased by 31,451,075 shares during the reporting period[184] - The company has a stock incentive plan with a vesting period of 12 to 36 months, allowing for the release of 50% of the restricted stocks at specified intervals[194] - The company does not have a controlling shareholder, and the actual controller is Li Ping, who is also the chairman and general manager[196] - The company has not experienced any changes in its controlling shareholder during the reporting period[197]

Financial Performance - Operating revenue for the first nine months reached CNY 910,547,636.67, a significant increase of 158.91% year-on-year[7] - Net profit attributable to shareholders increased by 176.71% to CNY 91,894,725.72 for the first nine months[7] - Basic earnings per share rose by 184.35% to CNY 0.418[8] - The company reported a total profit of ¥87,897,179.26 for the first three quarters of 2020, compared to ¥38,471,331.92 in the same period of 2019, indicating a substantial growth[34] - Operating profit for the first three quarters of 2020 was ¥102,445,407.46, compared to ¥36,726,467.36 in the same period of 2019, an increase of 178.5%[29] - The company reported a net profit attributable to shareholders of ¥8,678,734.08 for Q3 2020, down from ¥10,131,002.62 in Q3 2019, a decrease of 14.3%[30] Cash Flow - Cash flow from operating activities surged to CNY 141,031,803.96, up 2,049.98% compared to the same period last year[7] - The cash flow from operating activities for the first three quarters of 2020 was ¥930,121,800.96, significantly higher than ¥286,689,679.27 in the same period of 2019[37] - The net cash flow from operating activities reached RMB 141,031,803.96, a dramatic increase of 2049.98% due to higher income and receivables recovery[17] - The net cash flow from operating activities for Q3 2020 was ¥179.20 million, compared to ¥12.58 million in Q3 2019, indicating a substantial increase of 1,325.5%[41] - The total cash inflow from operating activities included ¥864.11 million from sales of goods and services in Q3 2020, compared to ¥248.96 million in Q3 2019, representing a growth of 247.5%[41] Assets and Liabilities - Total assets increased by 25.67% to CNY 1,092,792,218.71 compared to the end of the previous year[7] - Current liabilities rose to CNY 431,427,758.99, compared to CNY 292,463,803.20, reflecting an increase of about 47.7%[22] - Total liabilities reached CNY 440,643,492.39, up from CNY 302,078,657.35, indicating a growth of around 46%[22] - Owner's equity totaled CNY 652,148,726.32, compared to CNY 567,523,313.99, which is an increase of about 14.9%[22] - Cash and cash equivalents increased by 68.11% to RMB 325,573,594.12, primarily due to the recovery of receivables[15] Shareholder Information - The total number of shareholders reached 21,884 by the end of the reporting period[12] - Major shareholder Li Ping holds 44.47% of the shares, with 58,410,474 shares pledged[12] Operating Costs and Expenses - The company reported a 124.56% increase in operating costs, totaling RMB 606,412,945.50, in line with the rise in revenue from protective products[16] - Sales expenses skyrocketed by 1475.59% to RMB 135,712,056.78, driven by increased agency service fees and transportation costs[16] - The company’s total operating costs for Q3 2020 were ¥136,780,333.31, which is a 44.4% increase from ¥94,678,693.59 in Q3 2019[34] Government Subsidies - The company reported government subsidies amounting to CNY 1,238,068.23 for the first nine months[9] Research and Development - Research and development expenses for Q3 2020 amounted to ¥9,325,728.81, up from ¥5,660,150.18 in Q3 2019, marking a 64.5% increase[28]

Financial Performance - The company's operating revenue for the first half of 2020 was CNY 729,093,174.95, representing a 226.62% increase compared to CNY 223,225,891.37 in the same period last year[20]. - The net profit attributable to shareholders for the first half of 2020 was CNY 83,215,991.64, a 260.57% increase from CNY 23,079,272.95 in the previous year[20]. - The net cash flow from operating activities was CNY 141,696,341.32, compared to a negative cash flow of CNY 12,204,399.52 in the same period last year[20]. - Basic earnings per share for the first half of 2020 were CNY 0.38, up 245.45% from CNY 0.11 in the same period last year[22]. - The weighted average return on net assets increased by 9.79 percentage points to 13.85% compared to 4.06% in the previous year[22]. - Operating revenue increased to ¥729,093,174.95, a 226.62% increase compared to ¥223,225,891.37 in the same period last year[53]. - Operating profit for the first half of 2020 was ¥94,449,643.41, compared to ¥26,151,929.74 in the first half of 2019, indicating a year-over-year increase of about 261%[123]. - Net profit for the first half of 2020 was ¥83,477,737.27, up from ¥22,704,537.01 in the same period of 2019, reflecting an increase of approximately 267%[123]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,087,433,009.37, a 25.05% increase from CNY 869,601,971.34 at the end of the previous year[21]. - The total liabilities increased to ¥442,042,904.56 from ¥247,343,163.58, representing a rise of approximately 78.7%[120]. - The company’s fixed assets grew to ¥224,750,956.49, a 195.14% increase from ¥76,149,734.41 year-over-year, primarily due to project capitalization[56]. - Total current assets increased to CNY 714,036,257.74 as of June 30, 2020, up from CNY 501,453,608.69 at the end of 2019, representing a growth of 42.4%[114]. - Total liabilities increased to CNY 444,437,725.10 as of June 30, 2020, up from CNY 302,078,657.35 at the end of 2019, reflecting a rise of 47.1%[116]. Cash Flow - The company reported a significant increase in cash and cash equivalents, reaching ¥294,620,446.65, up 54.45% from ¥190,758,649.30 year-over-year[56]. - The cash flow from operating activities generated a net amount of ¥141,696,341.32, a turnaround from a negative cash flow of ¥12,204,399.52 in the same period last year[128]. - The total cash inflow from operating activities was ¥860,130,981.24, compared to ¥171,361,466.34 in the previous year, marking an increase of approximately 403%[128]. - The total cash outflow from operating activities was ¥718,434,639.92, compared to ¥183,565,865.86 in the previous year, reflecting a rise of about 291%[128]. Market Position and Strategy - The company specializes in the research, production, and sales of transdermal products, medical adhesive tapes, bandages, first aid kits, sports protective gear, and nursing products, positioning itself within the pharmaceutical manufacturing industry[27]. - The company has established a strong market presence in the medical device manufacturing industry, becoming a leading producer of adhesive bandages in China[35]. - The adhesive plaster market in China is experiencing rapid growth due to high demand for pain relief products, with transdermal absorption technology improving sales performance[34]. - The company has formed strategic partnerships for research and development, including collaborations with Zhejiang University and the Army Medical Center[39]. Product Development and Innovation - The increase in main business income was primarily due to the surge in sales of protective products related to epidemic prevention[22]. - The company has achieved significant technological advancements in product development, including high-water-absorption hydrogel preparation technology and precision adjustment mold technology[38]. - The company is actively developing new products, including vehicle-mounted first aid kits and low-allergen medical bandages, to enhance its competitive edge[46][47]. Risk Management - The company did not have any significant risks that could materially affect its production and operations during the reporting period[7]. - The company is facing risks related to market competition, particularly in the low-end medical dressing market, which is highly competitive[66]. - The company anticipates potential risks from currency fluctuations, as its export revenue is primarily settled in USD and EUR[67]. - The company is experiencing operational disruptions due to the pandemic, affecting production, procurement, and sales activities[69]. Shareholder and Governance - The controlling shareholder has committed to not transferring or entrusting management of their shares for 36 months post-listing[74]. - The company plans to repurchase shares at a price not exceeding 110% of the latest audited net asset value per share[76]. - The company has established measures to ensure that controlling shareholders do not interfere with management and will fulfill their commitments to compensate for any dilution of immediate returns[81]. Compliance and Regulations - The company has obtained multiple certifications, including GMP, ISO13485, CE, and FDA registrations, enhancing its market competitiveness[41]. - The company emphasizes its commitment to environmental protection, adhering to national laws and regulations without any violations during the reporting period[92]. - The financial statements are prepared in accordance with the enterprise accounting standards, reflecting the company's financial position and operating results accurately[159]. Accounting Policies - The company has not reported any significant changes in its accounting policies or estimates during the reporting period[158]. - The company follows specific accounting policies for mergers and acquisitions, treating them based on control and fair value assessments[163][165]. - The company recognizes financial liabilities at fair value, with changes in fair value recognized in profit or loss[181].

Financial Performance - The company's operating revenue for 2019 was CNY 491,688,011.57, an increase of 2.47% compared to CNY 479,823,815.86 in 2018[20]. - The net profit attributable to shareholders of the listed company decreased by 28.53% to CNY 28,051,595.53 from CNY 39,250,119.36 in the previous year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 7.45% to CNY 23,084,715.39 from CNY 21,483,869.91 in 2018[20]. - The net cash flow from operating activities was CNY 32,994,069.13, a decrease of 37.45% compared to CNY 52,749,492.03 in 2018[20]. - The total assets at the end of 2019 were CNY 869,601,971.34, reflecting a 2.81% increase from CNY 845,813,968.47 at the end of 2018[20]. - Basic earnings per share decreased by 26.09% to CNY 0.17 compared to CNY 0.23 in the previous year[21]. - The weighted average return on equity decreased by 2.19 percentage points to 5.02% from 7.21% in the previous year[21]. - The company reported quarterly revenues of CNY 140,006,043.51 in Q4 2019, with a total annual revenue of CNY 491,688,011.57[23]. - The net profit attributable to shareholders in Q4 2019 was a loss of CNY 5,158,680.04, contrasting with profits in the previous three quarters[23]. Dividend and Capital Management - The company plans to distribute a cash dividend of CNY 0.5 per 10 shares, totaling CNY 8,450,000 (including tax) based on a total share capital of 169,000,000 shares as of December 31, 2019[5]. - The company intends to increase its share capital by 3 shares for every 10 shares held from capital reserves, resulting in a new total share capital of 219,700,000 shares[5]. - The cash dividend policy stipulates that at least 25% of distributable profits should be allocated as cash dividends, with higher percentages for mature companies without major capital expenditure plans[109]. - The profit distribution plan for 2019 is subject to approval at the annual shareholders' meeting[113]. - The company reported a net profit of RMB 28,051,595.53 for 2019, with a dividend payout ratio of 30.12%[115]. Market and Product Development - The company specializes in the development, production, and sales of transdermal products, medical adhesive tapes, and emergency kits, among others[29]. - The product range includes transdermal patches, dressings, medical tapes, and sports protection products, indicating a focus on healthcare and safety[30]. - The company aims to expand its market presence in the medical manufacturing industry, particularly in the production of sanitary materials and medical supplies[29]. - The company has focused on developing its own brand products, such as first aid kits and protective gear, to expand its market presence[33]. - The company is actively working on the transformation of research results from collaborative projects, particularly in low-allergen and high-drug-loading new transdermal carriers[51]. Research and Development - Research and development expenses increased by 11% to RMB 22.30 million compared to the previous year[58]. - The total R&D expenditure for the period was CNY 22,299,855.95, accounting for 4.54% of total operating revenue[69]. - The number of R&D personnel was 85, representing 12.04% of the total workforce[69]. - The company has established a joint research center with Zhejiang University, focusing on new transdermal formulations, achieving preliminary success and applying for related patents[42]. - The company will increase its investment in research and development, particularly in new medical dressings and polymer materials, to enhance its technological strength[100]. Operational Efficiency and Management - The company adopts an "order-based production" model, aligning procurement with customer orders to ensure efficient production and inventory management[32]. - The company has established a strict supplier evaluation mechanism, assessing suppliers based on qualifications, manufacturing capabilities, and delivery performance, ensuring quality and reliability[32]. - The company has implemented a comprehensive management system covering product R&D, procurement, production, sales, and after-sales service, effectively controlling costs and improving profitability[45]. - The company has a structured approach to protect shareholder rights and ensure fair treatment of minority investors[146]. - The company has established a compensation and assessment committee to link the income of senior management closely with management performance and operational results[193]. Risks and Compliance - There were no significant risks that materially affected the company's operations during the reporting period[7]. - The company emphasizes that forward-looking statements in the report do not constitute substantive commitments to investors and advises caution regarding risks[6]. - The company faces risks from industry policy changes, intensified market competition, and fluctuations in foreign exchange rates that could impact its operations[105]. - The company has not reported any significant changes in its financial reporting or accounting policies during the year[198]. - The audit report confirms that the financial statements fairly reflect the company's financial position as of December 31, 2019, and its operational results for the year[197]. Shareholder and Governance - The independent directors are responsible for reviewing and providing opinions on the profit distribution plan[110]. - The company has a commitment to communicate with minority shareholders regarding dividend proposals[110]. - The company has committed to ensuring the fulfillment of measures to compensate for the dilution of immediate returns to investors, with a focus on optimizing investment returns and protecting the rights of small and medium investors[125]. - The company has established a social responsibility management system, focusing on employee welfare and training, ensuring compliance with labor laws[146]. - The company actively maintains investor relations, utilizing various communication channels to engage with shareholders and industry analysts[188].

Financial Performance - Net profit attributable to shareholders increased by 1.41% to CNY 9,432,898.99 year-on-year[6] - Operating revenue decreased slightly by 0.08% to CNY 100,435,111.68 compared to the same period last year[6] - Basic earnings per share rose by 1.42% to CNY 0.05582[6] - Net profit for Q1 2020 was CNY 9,289,562.19, compared to CNY 9,414,948.60 in Q1 2019, reflecting a decrease of approximately 1.33%[27] - The company's revenue for Q1 2020 was ¥97,334,274.40, a decrease of 1.64% compared to ¥98,951,847.92 in Q1 2019[29] - Operating profit for Q1 2020 increased to ¥11,019,443.49, up 11.25% from ¥9,906,144.94 in Q1 2019[30] - Net profit for Q1 2020 was ¥9,814,291.57, representing a 16.63% increase from ¥8,414,347.10 in Q1 2019[30] Cash Flow - Net cash flow from operating activities showed a significant decline of 153.85%, amounting to -CNY 6,076,249.05[6] - Net cash flow from operating activities was negative at CNY -6,076,249.05, mainly due to increased material purchases[14] - Net cash flow from investing activities was negative at CNY -35,770,162.50, primarily due to project payments by subsidiaries[14] - The company reported a net cash outflow from operating activities of ¥6,076,249.05 in Q1 2020, compared to a net inflow of ¥11,284,653.07 in Q1 2019[32] - The company experienced a decrease in total cash flow from investing activities, with a net outflow of ¥35,770,162.50 in Q1 2020 compared to a net inflow of ¥34,238,330.04 in Q1 2019[32] - Cash and cash equivalents decreased by $3,167,225.94, while the previous period saw an increase of $50,354,322.32[36] - The ending balance of cash and cash equivalents was $113,883,347.89, down from $194,331,150.06 in the previous period[36] Assets and Liabilities - Total assets increased by 3.27% to CNY 898,068,339.05 compared to the end of the previous year[6] - Total liabilities increased to CNY 320,811,229.86 from CNY 302,078,657.35[20] - The company's total assets as of March 31, 2020, were CNY 870,207,701.31, an increase from CNY 818,265,479.84 at the end of 2019, representing a growth of about 6.35%[23] - Current assets totaled CNY 475,004,441.73 as of March 31, 2020, up from CNY 429,509,695.56 at the end of 2019, indicating an increase of approximately 10.59%[22] - The total liabilities as of March 31, 2020, were CNY 289,471,093.48, compared to CNY 247,343,163.58 at the end of 2019, reflecting an increase of approximately 17.0%[23] - The company's equity increased to CNY 580,736,607.83 from CNY 570,922,316.26, representing a growth of about 1.4%[23] Shareholder Information - The total number of shareholders at the end of the reporting period was 20,000[11] - The largest shareholder, Li Ping, holds 44.48% of the shares, with 75,162,750 shares pledged[12] Investment and Development - Non-recurring gains and losses totaled CNY 693,858.21, including CNY 666,350.52 from the disposal of non-current assets[9] - Long-term equity investments surged by 3508.13% to CNY 54,546,291.75, attributed to the completion of an investment in Jiangsu Pharmaceutical Company[14] - Investment income rose by 403.62% to CNY 1,458,660.29, primarily from external investment returns[14] - The company has not reported any significant new product developments or market expansion strategies in this quarter[13] - The company did not apply new revenue and lease standards for the current year[36] - The company did not have an audit report applicable for the current period[36] Expenses - The company reported a decrease in research and development expenses to CNY 3,709,559.07 from CNY 4,650,959.32, a reduction of about 20.2%[27] - Research and development expenses decreased to ¥3,709,559.07 in Q1 2020 from ¥4,650,959.32 in Q1 2019, a reduction of 20.2%[29]

Financial Performance - Net profit attributable to shareholders decreased by 36.75% to ¥33,210,275.57 for the period from January to September[7] - Basic and diluted earnings per share decreased by 35.48% to ¥0.20[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥31,520,598.12, a decrease of 8.44%[7] - The net profit for the first three quarters of 2019 was CNY 30,190,587.72, compared to CNY 30,032,373.15 in the same period of 2018, showing a slight increase[23] - The net profit attributable to the parent company for Q3 2019 was ¥10.13 million, compared to ¥14.06 million in Q3 2018, indicating a decrease of 28.5%[26] - The total profit for Q3 2019 was ¥10.63 million, down from ¥14.54 million in the same period last year, reflecting a decline of 26.5%[25] - Net profit for Q3 2019 was CNY 10,925,239.96, a decrease from CNY 12,176,896.84 in Q3 2018, representing a decline of approximately 10.3%[30] Revenue and Costs - Operating revenue increased slightly by 0.37% to ¥351,681,968.06 for the same period[7] - Total operating revenue for Q3 2019 was CNY 128,456,076.69, an increase from CNY 119,577,752.98 in Q3 2018, representing a growth of approximately 7.4%[23] - Total operating costs for Q3 2019 were CNY 118,889,898.24, compared to CNY 107,633,757.38 in Q3 2018, indicating an increase of about 10.5%[23] - The company's operating revenue for Q3 2019 was approximately ¥124.16 million, a slight increase from ¥123.10 million in Q3 2018, representing a year-over-year growth of 0.86%[28] - The company's operating costs for Q3 2019 were approximately ¥94.68 million, slightly lower than ¥94.76 million in Q3 2018, indicating a decrease of 0.1%[28] Assets and Liabilities - Total assets decreased by 5.14% to ¥802,378,421.15 compared to the end of the previous year[7] - Total assets as of September 30, 2019, amounted to CNY 776,225,185.38, down from CNY 822,676,871.96 at the end of 2018, a decrease of approximately 5.7%[21] - Total liabilities as of September 30, 2019, were CNY 207,093,825.85, compared to CNY 266,644,130.22 at the end of 2018, reflecting a decrease of about 22.3%[22] - Cash and cash equivalents decreased by 62.53% to ¥89,300,581.07 from ¥238,355,117.98 due to increased investment payments[13] - Cash and cash equivalents decreased to CNY 60,721,975.54 from CNY 159,033,336.75 year-over-year, a decline of approximately 61.9%[21] Cash Flow - Cash flow from operating activities decreased significantly by 77.32% to ¥6,559,671.95[7] - The net cash flow from operating activities decreased by 77.32% to ¥6,559,671.95 from ¥28,922,098.11, primarily due to increased procurement payments compared to the same period last year[14] - Cash inflow from operating activities for the first three quarters of 2019 was ¥270,020,074.27, an increase of 4.0% from ¥259,441,877.11 in the previous year[33] - Cash outflow from investing activities totaled ¥109,917,070.82, compared to ¥109,250,275.71 in the same period last year, resulting in a net cash flow from investing activities of -¥39,292,382.15[34] - The net cash flow from financing activities decreased by 104.18% to -¥57,502,114.92 from -¥28,162,827.60, primarily due to short-term borrowings[14] Shareholder Information - Total number of shareholders reached 10,492 at the end of the reporting period[12] - The largest shareholder, Li Ping, holds 44.48% of the shares, with 75,162,750 shares pledged[12] Research and Development - The company reported R&D expenses of CNY 5,660,150.18 for Q3 2019, compared to CNY 6,657,667.49 in Q3 2018, a decrease of approximately 15%[23] - The company's R&D expenses for Q3 2019 were ¥5.66 million, a decrease from ¥6.66 million in Q3 2018, showing a reduction of 15.0%[28] Other Financial Metrics - The weighted average return on equity decreased by 3.62 percentage points to 5.79%[8] - The company's total assets impairment loss for Q3 2019 was ¥420.36 million, compared to a gain of ¥4.62 million in Q3 2018, marking a significant change[24] - The company's financial expenses for Q3 2019 were ¥1.71 million, compared to a gain of ¥1.34 million in Q3 2018, indicating a shift in financial performance[28] - The company's tax expenses for Q3 2019 were ¥1.11 million, down from ¥1.59 million in Q3 2018, reflecting a decrease of 30.0%[25]

Financial Performance - The company's operating revenue for the first half of 2019 was CNY 223,225,891.37, a decrease of 3.28% compared to CNY 230,793,324.29 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was CNY 23,079,272.95, down 39.97% from CNY 38,445,555.64 in the previous year[19]. - The net cash flow from operating activities was negative CNY 12,204,399.52, a decline of 140.70% compared to CNY 29,989,139.78 in the same period last year[19]. - The basic earnings per share decreased to CNY 0.14, down 39.13% from CNY 0.23 in the previous year[20]. - The weighted average return on net assets was 4.06%, a decrease of 2.92 percentage points compared to 6.98% in the previous year[21]. - The total assets at the end of the reporting period were CNY 831,102,180.26, a decrease of 1.74% from CNY 845,813,968.47 at the end of the previous year[19]. - The net assets attributable to shareholders of the listed company increased slightly by 0.41% to CNY 559,004,746.93 from CNY 556,725,473.98 at the end of the previous year[19]. - The company reported a decrease in net profit primarily due to the absence of non-operating income from land recovery by the government, which occurred in June 2018[21]. - The company reported a total non-recurring profit and loss of 1,146,083.33, with significant contributions from government subsidies amounting to 436,698.02 and entrusted investment management gains of 844,804.86[23]. Operational Efficiency - The company employs an "order-based procurement" model, aligning raw material purchases with customer orders, which enhances operational efficiency[27]. - The production model is based on "sales-driven production," allowing the company to adapt to customer demands and maintain service quality for long-term partners[29]. - The company has established a strict supplier selection mechanism, evaluating suppliers based on qualifications, manufacturing capabilities, and quality management systems[28]. - The company has a comprehensive procurement management system to ensure the quality of materials and regulate procurement processes[27]. - The company has implemented a comprehensive management system covering product R&D, technical innovation, procurement, production, sales, and after-sales service, effectively controlling costs and improving profitability[42]. Market Position and Strategy - The company specializes in the development, production, and sales of transdermal products, medical adhesive tapes, bandages, sports protection products, first aid kits, and nursing products, positioning itself within the pharmaceutical manufacturing industry[25]. - The company is expanding its product line under its own brand, focusing on first aid kits, sports protection products, and nursing products, in addition to its existing "Miaoshou" series[29]. - The company collaborates with Yunnan Baiyao Group, producing products under a long-term partnership, which includes specific production tasks and quality management agreements[29]. - The company has established a strong market influence in the medical device manufacturing sector after over 20 years of operation, becoming a leading producer of adhesive bandages in China[36]. - The company has focused on enhancing its core competitiveness through technological advancements in various production techniques, maintaining a leading position in the industry[38]. - The company has benefited from national policies supporting the medical device industry, which is considered a strategic priority for the country's healthcare development[31]. Research and Development - The company has established a collaborative research platform with Zhejiang University, focusing on the development of new transdermal formulations, achieving preliminary success and applying for relevant patent licenses[39]. - The company has developed high-end functional dressings and military emergency kits, enhancing its expected profitability and overall risk resistance[40]. - The company's R&D expenses increased by 38.26% to RMB 11,062,826.26 from RMB 8,001,570.07 in the previous year[51]. - The company has a stable R&D team and mature product formulas to support its expansion in the cosmetics sector[79]. Shareholder and Capital Management - The company did not propose any profit distribution plan or capital reserve transfer to increase share capital during the reporting period[5]. - The company plans to repurchase shares within 90 days at a price not exceeding 110% of the latest audited net asset per share, with a minimum repurchase quantity of 3% of total shares[71]. - The controlling shareholder, Li Ping, will increase his holdings of the company's shares within 90 days at a price not exceeding 110% of the latest audited net asset per share, with a minimum increase of 3% of total shares[71]. - The company has committed to ensuring that the shareholding structure remains compliant with listing conditions after any repurchase or increase in holdings[71]. - The company plans to distribute a cash dividend of RMB 1.6 per 10 shares, totaling RMB 20.8 million, based on a total share capital of 130 million shares as of December 31, 2018[93]. Environmental and Compliance - The company has implemented measures for wastewater treatment, ensuring that all wastewater is processed at a centralized facility[84]. - The company operates two gas boilers, consuming 1.5 million cubic meters of natural gas annually, with emissions meeting the required standards[85]. - The company has established a solid waste management system, ensuring hazardous waste is handled by qualified units[86]. - The company has not experienced any environmental pollution incidents in the first half of the year[87]. - The company has obtained various certifications including GMP, ISO13485, and CE, ensuring compliance with international quality standards[66]. Financial Reporting and Governance - The company has retained the accounting firm Lixin for the 2019 financial and internal control audit, with no changes during the reporting period[81]. - There were no significant lawsuits or arbitration matters during the reporting period[81]. - The company maintained good integrity status, with no unfulfilled court judgments or significant overdue debts[81]. - The company has not disclosed any major related party transactions during the reporting period[83]. - The company has not reported any major accounting errors requiring restatement during the reporting period[89].